Moxifloxacin

Moxifloxacin is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

COVID-19 December 2020 Update: Therapies and VaccinesCOVID-19 December 2020 Update: Therapies and Vaccines

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Managing Sleep Problems during COVID-19Managing Sleep Problems during COVID-19

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Acute exacerbations of chronic bronchitis (AECB)
  • Acute bacterial sinusitis (ABS)
    • Use for AECB and ABS indications should be avoided for routine use due recent FDA warning (Black Box warning) regarding serious and potentially permanent side effects (tendonitis and tendon rupture, peripheral neuropathy, and CNS side effects).
    • FDA safety warning regarding fluoroquinolone use
  • Community-acquired pneumonia
  • Skin and skin structure infections (including complicated)
  • Complicated intra-abdominal infections
  • Bacterial conjunctivitis (ophthalmic drops)

NON-FDA APPROVED USES

  • Treatment of M. tuberculosis including MDR and XDR-TB (in combination with other agents)
  • Treatment of MAI and other non-TB mycobacterial infections (in combination with other agents)
  • Alternative therapy for treatment of S. pneumoniae and H. influenzae meningitis in patients who have severe penicillin allergies.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Acute exacerbations of chronic bronchitis (AECB)
  • Acute bacterial sinusitis (ABS)
    • Use for AECB and ABS indications should be avoided for routine use due recent FDA warning (Black Box warning) regarding serious and potentially permanent side effects (tendonitis and tendon rupture, peripheral neuropathy, and CNS side effects).
    • FDA safety warning regarding fluoroquinolone use
  • Community-acquired pneumonia
  • Skin and skin structure infections (including complicated)
  • Complicated intra-abdominal infections
  • Bacterial conjunctivitis (ophthalmic drops)

NON-FDA APPROVED USES

  • Treatment of M. tuberculosis including MDR and XDR-TB (in combination with other agents)
  • Treatment of MAI and other non-TB mycobacterial infections (in combination with other agents)
  • Alternative therapy for treatment of S. pneumoniae and H. influenzae meningitis in patients who have severe penicillin allergies.

There's more to see -- the rest of this entry is available only to subscribers.